Kura Oncology Announces Participation in Key Investor Events

Author: Henry Turner Updated: 08-28-2025 07:59 AM

Kura Oncology to Engage Investors in Upcoming Conferences

Kura Oncology, Inc. (NASDAQ: KURA), a biotech firm specializing in precision medicines for cancer treatment, is set to showcase its latest advancements at three significant investor events this September. As a clinical-stage organization, Kura is committed to transforming cancer treatment through innovative therapies designed to target specific cancer pathways.

Scheduled Conferences

Cantor Global Health Conference

The first conference will be held on Thursday, September 4, at 8:35 a.m. ET. This is an essential venue for Kura to connect with potential investors and present its pipeline of promising drug candidates.

H.C. Wainwright 27th Annual Global Investment Conference

Following this, Kura will participate in the H.C. Wainwright conference on Monday, September 8, at 1:00 p.m. ET. This conference provides Kura with a platform to highlight its unique approach to cancer treatment and the progress of its clinical trials.

Morgan Stanley 23rd Annual Global Healthcare Conference

The final conference in September is the Morgan Stanley event on Wednesday, September 10, at 1:50 p.m. ET. Here, Kura is expected to share insights into its cutting-edge research and ongoing developments in the field of oncology.

Webcasts and Future Accessibility

Kura will provide live webcasts for all presentations, allowing investors who can't attend in person to engage with the discussions. Additionally, recordings of the webcasts will be available following each event for those who wish to review the information at their convenience.

About Kura Oncology

Kura Oncology is at the forefront of developing small-molecule drug candidates aimed at targeting pivotal cancer signaling pathways. The company focuses on high-need hematologic malignancies and solid tumors. Notably, Kura is advancing ziftomenib, a menin inhibitor that specifically targets genetic drivers of acute myeloid leukemias, and is committed to overcoming challenges related to resistance mechanisms in solid tumor treatments.

Company Contacts

For inquiries, investors and media can reach Greg Mann at 858-987-4046 or via email at gmann@kuraoncology.com. Kura is dedicated to providing ongoing updates and transparency regarding its research and development strategies.

Frequently Asked Questions

What are the key highlights of Kura Oncology's participation in upcoming conferences?

Kura Oncology will discuss its innovative cancer treatments and provide updates on its clinical trial progress at three prominent investor conferences in September.

When can investors watch the webcasts of Kura's presentations?

Live webcasts will be available during each presentation, with recordings accessible afterwards for those unable to attend the live events.

What is ziftomenib?

Ziftomenib is a menin inhibitor developed by Kura Oncology, targeting specific genetic factors associated with acute myeloid leukemias.

How does Kura Oncology approach cancer treatment?

Kura Oncology focuses on precision medicine, developing treatments that specifically target the biological mechanisms underlying cancer.

Who can provide more information about Kura Oncology?

Investors and media can contact Greg Mann at Kura Oncology for further inquiries.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.